AACP
COLL icon

Advantage Alpha Capital Partners’s Collegium Pharmaceutical COLL Stock Holding History

Advantage Alpha Capital Partners’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,531
Closed -$459K – 133
2025
Q2 		$459K Sell
15,531
-3,630
-19% -$104K 0.12% 102
2025
Q1 		$572K Buy
+19,161
New +$586K 0.14% 97
2024
Q4 		– Sell
-8,813
Closed -$341K – 158
2024
Q3 		$341K Buy
+8,813
New +$314K 0.08% 155

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Advantage Alpha Capital Partners's COLL Position: Q3 2025 in Review

Advantage Alpha Capital Partners sold out of Collegium Pharmaceutical (COLL) in Q3 2025, closing a stake of 15,531 shares — an estimated $459K sold.

Advantage Alpha Capital Partners first reported a position in COLL in Q3 2024 and held it in 3 quarters. The position peaked at $572K in Q1 2025. 244 funds tracked by Wall St. Rank hold COLL as of Q3 2025.

  • Advantage Alpha Capital Partners reported no remaining Collegium Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 15,531 Collegium Pharmaceutical shares in Q3 2025, an estimated $459K.
  • Advantage Alpha Capital Partners first reported a position in Collegium Pharmaceutical in Q3 2024 and held it in 3 quarters.
  • Advantage Alpha Capital Partners's Collegium Pharmaceutical position peaked at $572K in Q1 2025.
  • 244 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q3 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q3 2025, filed 12 Nov 2025.